Featured Review: Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema

The findings of this Cochrane Review may challenge the prescribing of H1 antihistamines for patients with eczema.This Cochrane Review assessed theeffects of oral H1 antihistamines as'add-on'therapy to topical treatment in adults and children with eczema. Are H1 antihistamines taken as tablets or liquid, effective and safe in people of any age with diagnosed eczema, if given in addition to creams and ointments, compared to treatment with an inactive substance (placebo) or nothing added to creams and ointments?Eczema (also known as'atopic eczema/dermatitis') is a skin disorder frequently affecting both children and adults. In developed countries, 10% to 20% of all people are affected by eczema during their lifetime. The main symptom is itch, which results in scratching and, together with skin inflammation, frequently produces reddening of the skin. The symptoms of eczema can lead to sleeplessness and fatigue, lowering quality of life. Antihistamines are frequently given for itch (specifically H1 antihistamines taken by mouth), and they may alleviate the symptoms of eczema when given in addition to conventional treatments directly applied to the skin (e.g. emollients, moisturisers, steroid creams), although they are not thought to cure it.Many antihistamines are available without prescription, for instance, cetirizine or loratadine. Although H1 antihistamines are frequently prescribed for treating eczema, we do not know whether they are effective and safe. The review includes 25...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news

Related Links:

CONCLUSION: In this study, no influence of tear substitutes containing different viscosities of hyaluronic acid on the measurement results of optical coherence tomography could be determined. Therefore, 0.1%, 0.2% and 0.3% hyaluronic acid can be applied to the patient to improve the corneal surface before the examination with optical coherence tomography, without influencing the measurement results of optical coherence tomography. PMID: 33036058 [PubMed - as supplied by publisher]
Source: Klinische Monatsblatter fur Augenheilkunde - Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research
Conclusions: (1) Data at our center suggests at least a regional implementation gap in GBS screening and IAP. (2) The decline in the resistance rate ofE. coli for all antimicrobial substances might indicate that the reduction of prenatal antibiotics use is beneficial and that neonatal antibiotic stewardship programs should include pregnant women as well.What is Known:• GBS screening and intrapartum antibiotic prophylaxis led to a 32%-reduction in GBS disease in Germany with a 0.75 (92:122) ratio of early-onset disease to late-onset disease in 2009–2010.• Prenatal antibiotic use might increase the risk of E....
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
Publication date: February 2021Source: Learning and Instruction, Volume 71Author(s): Lea Nemeth, Katharina Werker, Julia Arend, Frank Lipowsky
Source: Learning and Instruction - Category: Psychiatry & Psychology Source Type: research
Conclusion:This study described alexithymia in AD patients correlating its occurrence with clinical AD severity markers (EASI score, itch, and sleeplessness) and identifying the increase in EASI score as predicting factor.Dermatology 2020;236:329 –335
Source: Dermatology - Category: Dermatology Source Type: research
CONCLUSIONS: We found lack of evidence to address our review question: for most of our interventions of interest, we found no eligible studies. The neurokinin 1 receptor (NK1R) antagonist serlopitant was the only intervention that we could assess. One study provided low-certainty evidence suggesting that serlopitant may reduce pruritus intensity when compared with placebo. We are uncertain of the effects of serlopitant on other outcomes, as certainty of the evidence is very low. More studies with larger sample sizes, focused on patients with CPUO, are needed. Healthcare professionals, patients, and other stakeholders may h...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
CONCLUSIONS: Based on the main comparisons, we did not find consistent evidence that H1 AH treatments are effective as 'add-on' therapy for eczema when compared to placebo; evidence for this comparison was of low and moderate quality. However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares. Cetirizine was no better than placebo in terms of physician-assessed clinical signs nor patient-assessed symptoms, and we found no evidence that loratadine was more beneficial than placebo, although all inte...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
CONCLUSIONS: For the following research, the authors suggest SCORAD (Total) as primary outcome and SCORAD (objective), VAS (Itch), VAS (insomnia), EASI, POEM, and DLQI as secondary outcomes. Thirty six participants should be conducted a 4-week acupuncture period (twice weekly) and a 4-week follow-up. It is necessary to compare the differences of general symptoms according to presence of epigastric tenderness or dyspepsia at the screening level. PMID: 30477869 [PubMed - in process]
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Tags: Complement Ther Med Source Type: research
ConclusionsSelf-reported adult-onset AD is common and has distinct phenotypes with lesional predilection for the hands and/or head/neck.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
urham S, Boyle RJ Abstract BACKGROUND: Specific allergen immunotherapy (SIT) is a treatment that may improve disease severity in people with atopic eczema (AE) by inducing immune tolerance to the relevant allergen. A high quality systematic review has not previously assessed the efficacy and safety of this treatment. OBJECTIVES: To assess the effects of specific allergen immunotherapy (SIT), including subcutaneous, sublingual, intradermal, and oral routes, compared with placebo or a standard treatment in people with atopic eczema. SEARCH METHODS: We searched the following databases up to July 2015: the C...
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Allegra | Children | Dermatitis | Dermatology | Eczema | Epidemiology | Fexofenadine | Germany Health | Information Technology | Insomnia | Itchiness | Skin | Study | Zyrtec